From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

Last Updated: Monday, May 16, 2022

A phase 1 trial demonstrated for the first time that infusing polyclonal healthy donor regulatory T cells followed by expansion with low-dose interleukin-2 is safe in patients with steroid-refractory chronic GvHD.

Blood
Advertisement
News & Literature Highlights
Advertisement
Advertisement